In The News: BIOSPACE
Biospace.com has posted an article detailing our efforts to combat COVID-19. Read more here: https://www.biospace.com/article/chicago-biotech-company-testing-its-monoclonal-antibody-to-treat-covid-19/
In The News: 1000 Longevity Leaders
We are pleased to announce that Lewis Gruber was recently named to the Aging Analytics Agency’s list of 1000 Longevity Leaders recognized in the research and academia sector for his work with SIWA Therapeutics. Aging Analytics is the longest-running and most comprehensive interactive platform of longevity professionals. The agency profiles public and private-sector influencers whose work in business, science, policy, philanthropy, or thought-leadership is instrumental in the longevity landscape.
BIO Digital 2020
SIWA Therapeutics is pleased to announce our participation in BIO Digital 2020, a virtual gathering of the global biotech industry. BIO is the world's largest trade association, which represents biotechnology companies, academic institutions, and other organizations on the forefront of innovation. This year, the BIO International Convention will transition into an entirely virtual event, providing even closer access to key partners via the BIO One-on-One Partnering. We look forward to our discussions at this year’s unique platform on June 8-12! If attending, please reach out to us partners@siwatherapeutics.com
In the News: SIWA Featured on Chicago Business Journal
Our founder and Chief Scientific Officer, Lewis Gruber recently spoke with Jim Dallke, Senior Editor of AmericanInno and contributor to American City Business Journals about SIWA Therapeutic’s groundbreaking work to defeat aging and age-related diseases. Read more here: https://www.bizjournals.com/chicago/news/2020/03/25/startup-siwa-therapeutics-aims-to-find-a-cure-for.html
In the News: SIWA Therapeutics Joins the Ranks of SpaceX, Apple & Google with Our Inclusion in MIT Technology Reviews Top 10 Breakthrough Technologies of 2020.
MIT Technology Review selected Anti-Aging Drugs as one of the Top 10 Breakthrough Technologies of 2020 and included SIWA Therapeutics as a “key player” in the category. Read more here: http://tinyurl.com/whvg437
In the News: Lewis and Misty Gruber Were Interviewed by Lifespan.io
Lewis and Misty Gruber discuss how SIWA 318H, the company’s humanized monoclonal antibody, binds to a biomarker of oxidative stress found on senescent cells and cancer cells as well as dysfunctional cells in general. https://www.lifespan.io/news/lewis-gruber-senotherapeutics/
In the News: Forbes
SIWA therapeutics was mentioned in an article at Forbes! See what they had to say about senolytic therapies and the future of aging.
SIWA Therapeutics: A New Supernova to Discover!
Meet SIWA Therapeutics, the startup challenging aging, cancer and degenerative diseases. Senescent cells (cells that have stopped dividing due to damage) are causally connected with aging and aging-related diseases, including cancer. “While they don’t divide like cancer cells, senescent cells are highly active metabolically,” explains SIWA co-founder and CEO, Lewis Gruber. “They can poison the tumor micro-environment — inducing, progressing and metastasizing cancer in the cells around them.” Therefore, Gruber and SIWA developed a monoclonal antibody, SIWA 318H, that is sensitive to a marker appearing on both senescent cells and cancer cells, ultimately binding to the cell, destroying it and removing the debris. “In our first in-vivo study, we successfully removed the senescent cells,” explains SIWA co-founder and Chief Strategy Officer, Misty Gruber. “In the second in-vivo study, we reduced…
DR. THOMAS TANG JOINS SIWA THERAPEUTICS SCIENTIFIC ADVISORY BOARD
SIWA Therapeutics, Inc., a privately held biotechnology company developing a family of monoclonal antibodies to prevent, slow or reverse aging, aging-related and degenerative diseases by reducing senescent cells, announced today that Dr. Thomas Tang has joined its Scientific Advisory Board. Dr. Tang is the CEO of First Dimension BioSciences, a genetic information database company focusing on cancer genomes to establish a statistical compendium of mutation profiles in a state-of-the-art computational data center. He has over 20 years of experience in genomics and bioinformatics research. “Dr. Tang’s addition to the SIWA team will resurrect a productive past partnership,” said Lewis Gruber, co-founder and chief executive officer of SIWA. ‘Tom was one of the early scientists at my first company, Hyseq, Inc. He was a key player in developing Hyseq’s genomics database…
Second Annual Healthspan Extension Policy and Regulation Workshop
The afternoon featured four presentations. First, Lewis Gruber, CEO of SIWA Corporation, provided an update on removing senescent cells as an anti-aging strategy, including presenting results of an anti-senescent cell monoclonal antibody his company is developing. Link